The comparison of 0.5mg dutasteride and 1mg finasteride for treating hair loss in men with androgenetic alopecia, with discussion of which is more effective and has fewer side effects.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
User shared 1-year progress using finasteride 1mg and minoxidil, regaining hair density. Others praised the improvement and asked about side effects and additional treatments.
The conversation is about a finding that finasteride does not significantly increase the risk of sexual dysfunction, with users sharing mixed personal experiences regarding side effects.
A user experienced severe side effects from finasteride, including mental health issues and physical symptoms, and sought advice on managing post-finasteride syndrome. Suggestions included checking vitamin levels, considering dopamine agonists, and avoiding further psychiatric medications.